Area of research
Reproductive Medicine · Obstetrics and Gynecology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Uterine Myomas and Treatments, and Endometrial and Cervical Cancer Treatments.
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial
Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas.
Figure S9 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S14 from Dissecting the origin of heterogeneity in uterine and ovarian carcinosarcomas
Figure S5 from Dissecting the origin of heterogeneity in uterine and ovarian carcinosarcomas
Figure S1 from Dissecting the origin of heterogeneity in uterine and ovarian carcinosarcomas
Figure S12 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Supplementary Table 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S8 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S9 from Dissecting the origin of heterogeneity in uterine and ovarian carcinosarcomas
Figure S5 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
FIGURE 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S8 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S6 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S11 from Dissecting the origin of heterogeneity in uterine and ovarian carcinosarcomas
Figure S15 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Supplementary Table 2 from Dissecting the origin of heterogeneity in uterine and ovarian carcinosarcomas
Figure S11 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Supplementary Table 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S13 from Dissecting the origin of heterogeneity in uterine and ovarian carcinosarcomas
Supplementary Table 1 from Dissecting the origin of heterogeneity in uterine and ovarian carcinosarcomas
Figure S7 from Dissecting the origin of heterogeneity in uterine and ovarian carcinosarcomas
Figure S15 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Figure S1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas